VAE Questions and Case Studies
|
|
- Samantha Owens
- 6 years ago
- Views:
Transcription
1 VAE Questions and Case Studies Cindy Gross, MT, SM (ASCP), CIC IP Consultant April 30, 2014 National Center for Emerging and Zoonotic Infectious Diseases Division of Healthcare Quality Promotion Review the process of detering the daily imum and FiO2 values Review the necessary criteria needed to meet the first tier of the VAE algorithm (VAC) Highlight a few FAQs Identify the VAE specific event definition that is met based on example data provided 1
2 Respiratory status component VAE Definition Algorithm Summary Patient on mechanical ventilation > 2 days Baseline period of stability or improvement, followed by sustained period of worsening oxygenation Ventilator-Associated Condition(VAC) No CXR needed! Infection / inflammation component General evidence of infection/inflammation Infection-Related Ventilator-Associated Complication (IVAC) Additional evidence Positive results of microbiological testing Possible or Probable VAP Daily Minimum FiO 2 and FiO 2 and ventilator settingsdocumented across the calendar day are used to identify the daily imum FiO 2 and values FiO 2 and settings are typically recorded in the paper or electronic medical record, on respiratory therapy and/or nursing flow sheets, in the section of the flow sheet that pertains to respiratory status/mechanical ventilation Use a calendar day not some other capture period or other designated 24 hour time period Choose the lowest FiO 2 and setting during the calendar day that was maintained for at least 1 hour 2
3 Daily Minimum FiO2 and When choosing the daily imum and FiO 2, use all settings that are recorded during times when the patient is receiving support from an eligible mode of mechanical ventilation and the patient is eligible for VAE surveillance Include settings collected during weaning/mechanical ventilation liberation trials as long as the patient is receiving ventilator support during those trials Use all conventional mechanical ventilation settings Include conventional MV settings during times when a patient is intermittently on an excluded mode of ventilation throughout a calendar day Include recorded settings during times when a patient is not on APRV or a similar mode of ventilation. Daily Minimum FiO 2 and Use the daily imum FiO 2 and values when assessing for both the period of stability or improvement and the period that indicates worsening oxygenation. Do not compare values that occur within a calendar day to detere stability, improvement or worsening. 3
4 Identifying the Minimum Daily FiO 2 and (Select the lowest value recorded for each calendar day that is maintained for at least one hour) Monday 12am 3am 6am 9am 12pm 3pm 6pm 9pm MV mode ACV ACV ACV ACV ACV ACV ACV ACV FiO O Note: Documentation of FiO 2 and occurs every 3 hour Detering daily imum /FiO2 when settings are documented 1 hour intervals Specific guidance in the found in the protocol Must be sufficient documentation of consecutive recordings to meet the imum required duration of 1 hour If tracking every 15 utes, 5 consecutive recordings of a certain level would be needed (e.g., at 09:00, 09:15, 09:30, 09:45 and 10:00 If tracking every 30 utes, 3 consecutive recordings at a certain level would be needed (e.g., at 09:00, 09:30, and 10:00) If tracking every hour, 2 consecutive recordings at a certain level (e.g., at 09:00 and 10:00) Standardization 4
5 Identifying the Minimum Daily FiO 2 and (Select the lowest value recorded for each calendar day that is maintained for at least 1 hour) Monday 12am 3am 4am 6am 9am 12pm 3pm 9pm MV mode ACV ACV ACV ACV ACV ACV ACV ACV FiO O is the lowest value for the calendar day but it was not maintained for 1 hour Daily Minimum Values The patient is intubated at 2 pm. and FiO 2 are set at the following values through the remainder of the calendar day. What are the daily imum and FiO 2 values for the calendar day? Time 2 pm 4 pm 6pm 8 pm 10 pm 12 am (cmh 2 O) FiO
6 What are the daily imum and FiO2? 1. 5 and and and and 1.0 Time 2 pm 4 pm 6pm 8 pm 10 pm 12 am (cmh 2 O) FiO Daily Minimum Values The patient is intubated at 6 pm. and FiO 2 are set at the following values through the remainder of the calendar day. What are the daily imum and FiO 2? Time 6 pm 7 pm 8 pm 9 pm 10 pm 11 pm (cmh 2 O) FiO
7 What are the daily imum and FiO2? 1. 5 and and and and 0.60 Time 6 pm 7 pm 8 pm 9 pm 10 pm 11 pm (cmh 2 O) FiO VAC Requirements Baseline period of stability or improvement Indicators of worsening oxygenation 7
8 Define Baseline MV Day Daily imum Daily imum FiO Define Baseline MV Day Daily imum Daily imum FiO
9 Define Baseline MV Day Daily imum Daily imum FiO Meeting VAC Definition What if the increase over the baseline period meets the requirement relative to one baseline day? MV Day Daily imum Daily imum FiO 2 1. VAC 2. NO VAC
10 Meeting VAC Definition What if there is an increase for one day and then a decrease? MV Day Daily imum Daily imum FiO 2 1. VAC 2. NO VAC Meeting VAC Definition VAC or No VAC? MV Day Daily imum Daily imum FiO Yes 2. No
11 Discrepant changes goes up but FiO 2 goes down MV Day Daily imum Daily imum FiO When should I use PNEU/VAP instead of VAE? A. Never always use VAE B. When surveillance is to be conducted in mechanicallyventilated children who are in pediatric locations C. When surveillance is to be conducted for healthcareassociated pneumonia that is not associated with mechanical ventilation D. Band C E. None of the above 11
12 NHSN Lower Respiratory Events in 2014 VAE is the only in-plan option available for ventilated patients in adult locations as of January Current VAP protocol is available for in-plan surveillance in pediatric locations ONLY. In-plan neonatal VAP surveillance is no longer available as of January 2014 In 2014, the current PNEU definitions are still available for off-plan surveillance of VAP in adults, children, neonates or off-plan surveillance for non-ventilated PNEU in adults, children or neonates. If a patient is admitted with a community acquired pneumonia (CAP), they are excluded from VAE surveillance for 14 days. A. True B. False 12
13 FALSE All patients who are eligible for VAE surveillance are to be included There are no exclusions for specific admitting diagnoses or underlying illnesses Algorithm requires a period of stability on the ventilator typically should not be capturing events that represent ongoing worsening If patient stabilizes or improves then worsens again, this is a possible indication of a new HAI Patients with CAP, may experience complications related to mechanical ventilation that are preventable If temperature, WBC or laboratory criteria are present prior to detection of a VAE and also present within the VAE Window Period, they canbe used to meet IVAC and possible or probable VAP definitions. A. True B. False 13
14 TRUE All abnormal temperature and white blood cell count values documented during the VAE Window Period are to be utilized Eligible laboratory findings (Gram stain, culture, other laboratory test results) that have a collection date during the VAE Window Period are to be utilized When evaluating patient data to see if the IVAC definition is met, I should focus onlyon antibiotics that are used to treat respiratory infections A. Yes B. No 14
15 IVAC and Antimicrobial Agents Meeting Infection-related Ventilator Associated Complication ( IVAC) definition does not mean that the infection related event is necessarily respiratory in origin. The IVAC antimicrobial list was refined by removing selected antimicrobial agents that would not be used, or would be unlikely to be used, in treating a lower respiratory infection in a critically ill patient. Still possible that an existing agent may have dual purposes and not necessarily be treating a respiratory infection. No need to discern the reason for the adistration of the antimicrobial. Prophylaxis, de-escalation, change within a class of antimicrobials is not a reason for exclusion When selecting the daily imum and FiO 2 for each calendar day.. 1. Throw out the lowest value 2. Choose the most consistent value 3. Select the value using any 24 hour time period 4. Choose the lowest value that has been maintained for at least 1 hour 15
16 A patient in my ICU met the IVAC definition. On the VAE Event Date, there was also a positive blood culture that grew Pseudomonas aeruginosa. The patient has a central line. Other than fever, there are no other signs/symptoms of infection. How should I report this event? A. Report an IVAC (no pathogen) and evaluate to see if the positive blood culture is secondary to another HAI or if it is a CLABSI (pathogen=pa) B. Report an IVAC (pathogen=pa) C. Report an IVAC and secondary BSI (pathogen=pa) D. Report a CLABSI (pathogen=pa) E. Report an IVAC (no pathogen) F. None of the above Secondary BSI can only be reported for possible or probable VAP Organisms isolated from the blood culture must match an organism isolated from an appropriate respiratory tract specimen that was used to meet the possible or probable VAP definition Blood culture must be collected during the 14 day event period If the blood culture is not found to be secondary to VAE look to the other HAI definitions (including PNEU and LRI) or report as a CLABSI VAC, IVAC or No VAE detected Possible or probable VAP met but no organism match and/or blood culture not collected during 14 day event period 16
17 If I am conducting VAE surveillance in-plan, I need to assess daily imum and maximum temperatures for the following patients: 1. All patients in the ICU 2. All patients in the ICU who are on a ventilator 3. Patients who I have detered meet the VAC definition 4. Patients who have met the VAC definition and also have an abnormal white blood cell count 5. Patients who the clinical care providers have diagnosed with VAP Key Things to Remember about Data Collection For most patients will only need to record daily imum and FiO 2 while on ventilator. Nothing else! Only need to assess temperature and white blood cell count information for patients who fulfill VAC criteria And only need to look at these values during the VAE Window Period (3-5 days) Only need to look at antimicrobial adistrations for patients with VAC AND abnormal temp or white count New during the VAE Window Period (3-5 days) Only need to assess lab/microbiology/pathology data for patients that meet the IVAC definition Collection dates during the VAE Window Period (3-5 days) 17
18 The following examples are for illustration purposes only and are not intended to represent actual clinical scenarios. Case Study 1 A 69-year old female is seen in the ER with an admitting diagnosis of community acquired pneumonia (CAP). She is admitted to the ICU the same day on a ventilator. Review her ventilator settings and detere if VAE criteria are met. MV Day Daily imum Daily imum FiO A. Yes B. No 18
19 What specific event should be reported for this patient? MV DAY Daily imum Daily imum FiO 2 Temp WBC ABX ABX Pip / Tazo Pip / Tazo Pip / Tazo Specimen Vanco- IV Vanco- IV Sputum Polys /Epis Organism Scant NF, Many Staph. aureus BAL Vanco- IV 10 4 cfu/ml S. aureus Vanco- IV What specific event should be reported for this patient? A. None, the patient had CAP present on admission B. Possible VAP (pathogen SA) C. Probable VAP (Pathogen SA) D. VAC only 19
20 MV DAY Daily imum Daily imum FiO 2 Temp WBC ABX ABX Pip / Tazo Pip / Tazo Pip / Tazo Specimen Vanco- IV Vanco- IV Sputum BAL Vanco- IV Polys /Epis Organism Scant NF, Many Staph. aureus 10 4 cfu/ml S. aureus Vanco- IV CASE 1 Recap Patients are not excluded from VAE surveillance due to admitting diagnosis, presence of underlying conditions or development of complications Eligible pathogens identified during the VAE window period are to be used to detere if possible or probable VAP definitions can be met even if the same or similar pathogen was identified prior to the event detection Days between adistration of the same new antimicrobial agent count as QADs as long as there is a gap of no more than 1 calendar day. 20
21 Case Study 2 A 17 year old female with cystic fibrosis is admitted to the adult medical ICU where in plan VAE surveillance has been selected in the monthly reporting plan. She is placed on the ventilator on hospital day 5. Based on the following findings do you need to report anything to NHSN. Case Study 2 Do you need to report anything to NHSN? FiO MV Day 2mi Polys / Temp Temp max WBC WBC max Abx Speci-men n Epis Organism None None None None None BAL 25 / cfu/ml Pseudomonas aeruginosa Yes Yes Yes Blood -- Staph aureus Yes Yes Yes Yes Yes Yes No No No
22 Case Study 2 1. Nothing to report to NHSN 2. Probable VAP with a secondary BSI (pathogens PA, SA) 3. Probable VAP (pathogen PA) 4. Probable VAP (pathogen PA) and perhaps a secondary BSI to another HAI site or CLABSI (pathogen SA) 5. Probable VAP (pathogen PA) and a CLABSI (pathogen PA) MV Day FiO 2mi n Temp Temp max WBC WBC max Abx Speci-men Polys / Epis Organism None None None None None BAL 25 / cfu/ml Pseudomonas aeruginosa Yes Yes Event Period (14 Days ) Yes Blood -- Staph aureus Yes Yes Yes Yes Yes Yes No No No
23 Case Study 2 Recap All patients in an adult location where VAE was selected in the monthly reporting plan are included Event Day 4 (first day of onset of worsening oxygenation) VAC met in FiO 2 parameter, do not round up values VAE Window Period is limited to 4 days, VAC and IVAC definitions are met Both purulent respiratory secretions and the quantitative culture criteria are met to satisfy the Probable VAP definition Blood culture is collected within the 14 day Event Period but the respiratory and blood culture pathogens do not match therefore, look to detere if another HAI definition is met for secondary bloodstream infection attribution and if not then report as CLABSI Case Study 3 An elderly gentleman is admitted to the trauma ICU following a motor vehicle accident. He had been intubated in the field and there was some concern of aspiration upon intubation. Given the following information, identify all events. 23
24 Case Study 3 Identify event(s) and MV day of event(s) MV Day FiO 2m in Temp Temp max WBC WBC max Abx Specimen Polys / Epis Organism None None None None None Yes BAL 25 / C. albicans Yes BC x2 -- C. albicans Yes Yes Yes Yes Yes None None Yes Yes Yes PATIENT EXPIRES Identify the event(s) and MV day 1. MV Day 6 - Probable VAP and MV Day 15 -VAC 2. MV Day 6 - Possible VAP 3. MV Day 15 - VAC 4. MV Day 6 -Probable VAP 24
25 MV Day Case Study 3 VAC MV Day 15 FiO 2m in Temp Temp max WBC WBC max Abx Specimen Polys / Epis Organism None None None None None BAL 25 / C. albicans Yes Yes BC x2 -- C. albicans Yes Yes Yes Yes Yes None None Yes -- 4 QAD Yes requirement Yes PATIENT EXPIRES not met Case Study 3 Recap Event Day 15 (first day of onset of worsening oxygenation) VAE Window Period is Day 13, 14 (two days before), Day 15 (event day), Day 16,17 (two days after) Abnormal WBC documented during VAE Window Period but only 3 QADs are observed prior to the patient expiring Baseline period of stability is not established early in mechanical ventilation episode No VAC, No IVAC, No Possible/Probable VAP 25
26 Case Study 3 Focus on identifying VAC No need to collect other parameters in advance Culture driven surveillance approach is not useful for VAE MV Day FiO PATIENT EXPIRES Case Study 4 Patient was admitted with a diagnosis of pneumonia and tested positive for Influenza A by PCR. On hospital day 3 she is placed on a ventilator. Does this patient have a VAC? A. Yes B. No Hosp Day MV Day Daily Daily Temp WBC ABX ABX ABX FiO ceftriaxone ceftriaxone ceftriaxone vancomycin vancomycin vancomycin Cefepime Cefepime vancomycin Cefepime Cefepime Cefepime 26
27 Case Study 4 After reviewing the medical record the additional data is collected. Does this patient satisfy the IVAC definition? A. Yes B. No Hosp Day MV Day Daily Daily Temp WBC ABX ABX ABX FiO ceftriaxone ceftriaxone ceftriaxone vancomycin vancomycin vancomycin Cefepime Cefepime 5 QADs vancomycin Cefepime Cefepime Cefepime Case Study 4 Recap Date of event is hospital day 5 / MV day 3 VAE Window Period is limited to 3 days Multiple antimicrobials were adistered but only one was considered to be new QADs can accumulate outside the VAE window period provided the agent is found to be new 27
28 Case Study 5 42 year old female dialysis patient was intubated and transferred from Hospital A to Hospital B on MV Day 1 for management of severe asthma exacerbation. The patient had been receiving vancomycinfor treatment of a BSI. Upon admission her temperature was 37.5⁰C and WBC count was 5.6 cells/mm. 3 On MV Day 3 during dialysis treatment the patient developed a temperature of 39.7⁰C. On MV Day 5 she had increased respiratory secretions and an endotracheal aspirate was sent for culture and Gram stain. On MV Day 7 imipenem was started. Case Study 5 Does this patient meet the criteria for VAE, and if so, what type of VAE? MV Day FiO 2 Temp Temp max WBC WBC max Abx Specimen Polys / Epis Organism Vanco None Vanco None Vanco ETA 25 / 10 Heavy K. pneumoniae None Imipenem Imipenem Imipenem Imipenem
29 Case Study 5 Does this patient meet the criteria for VAE, and if so, what type of VAE? A. VAC B. IVAC C. Possible VAP D. No VAE Case Study 5 MV Day FiO 2 Temp Temp max WBC WBC max Abx Specimen Polys / Epis Organism Vanco None Vanco day VAE Window None Vanco ETA 25 / 10 Heavy K. pneumoniae None Imipenem Imipenem Imipenem Imipenem
30 Case Study 5 Recap Event date is MV Day 4 (first day of worsening) Within the 4day window period Temperature elevation present However, no new antimicrobial agent was initiated and continued for 4 days (vancomycin is nota new antibiotic and imipenem was started outside the VAE Window Period) Specimen collection -purulent secretions AND qualifying positive culture present but if IVAC definition is not met you can not proceed to the next tier of the algorithm Event is attributable to Hospital B Preparing for VAE Surveillance Establish relationships with Respiratory Therapy and/or Critical Care colleagues: Share the protocol Discuss options for collection of imum daily and FiO 2 for each MV day (IP, RT, electronically generated) Inquire about frequency with which excluded therapies (HFV, ECLS) and APRV are used Detere your laboratory s approach to Gram stain and culture result reporting. How does your hospital laboratory report Gram stain results? Does your hospital laboratory report culture results quantitatively What quantitative ranges correspond to the semi-quantitative reports? 30
31 Preparing for VAE Surveillance Develop a plan for organizing the data elements needed to identify VAEs and FiO2 WBC / Temperature Antimicrobials agents (adistration not orders) Laboratory results Explore use of tools for data collection
32 Questions 32
33 THANK YOU! For more information please contact Centers for Disease Control and Prevention 1600 Clifton Road NE, Atlanta, GA Telephone, CDC-INFO ( )/TTY: Web: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. National Center for Emerging and Zoonotic Infectious Diseases Division of Healthcare Quality Promotion 33
Daily minimum Daily minimum. FiO What if the settings were as follows?
Ventilator - Associated Event Case Studies Cindy Gross, MT, SM (ASCP), CIC Division of Healthcare Quality Promotion Centers for Disease Control and Prevention October 4, 2012 The following examples are
More informationAn update on RSV surveillance in Canada. Dr. Christina Bancej SARINet - May 24, 2017
An update on RSV surveillance in Canada Dr. Christina Bancej SARINet - May 24, 2017 Objectives 1. To describe the current RSV surveillance landscape in Canada 2. To provide an update on Canada s progress
More information1.0 Abstract. Palivizumab P Study Results Final
1.0 Abstract Title: Prospective, Multi-Center, Observational Program to Assess RSV Hospitalization Rate in Population of Children at High-risk of Serious RSV Illness Who Received Palivizumab Immunoprophylaxis
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION March 2018 1 Forward Looking Statement This presentation includes statements relating to the company's Acuitas MDRO and Acuitas Lighthouse clinical laboratory services, FDA cleared
More informationRespiratory Syncytial Virus Severe Morbidity and Mortality
Respiratory Syncytial Virus Severe Morbidity and Mortality Marika K Iwane, PhD MPH CDC Division of Viral Diseases Respiratory/Picornavirus Team PAHO-Panama City May 29, 2014 National Center for Immunization
More informationNew Hampshire Healthcare-Associated Infections Annual NHSN Workshop: May 4, 2017 NHSN Analysis
New Hampshire Healthcare-Associated Infections Annual NHSN Workshop: May 4, 2017 NHSN Analysis Yvette Perron, MPH HAI Surveillance Coordinator Infectious Disease Surveillance Section Bureau of Infectious
More informationPHA 5128 Case Study # 4. Enter New Patient in Patient Assessment: Select Patient / New Patient and enter all information.
1. Gertrude Thompson MR #: 190522 Account #: 15028 Admission Date: 7/18/94 Physician: Jack Long, Infectious Disease Location: 4 West, Room 408, Bed C Female Black DOB: 2/5/1956 5 4 (163 cm), 220 lbs. (99.79
More informationNovel Approaches to Further Antibacterial Drug Development: New Approaches to the Clinical Development Program
Novel Approaches to Further Antibacterial Drug Development: New Approaches to the Clinical Development Program An industry view John H. Rex, Infection Clinical Vice President AstraZeneca Pharmaceuticals
More informationDiscovering the Optimal Approach to Diagnosing Clostridium difficile Infection (CDI) PRESENTED BY: NATHAN A. LEDEBOER, PHD, D(ABMM)
Discovering the Optimal Approach to Diagnosing Clostridium difficile Infection (CDI) PRESENTED BY: NATHAN A. LEDEBOER, PHD, D(ABMM) PROFESSOR OF PATHOLOGY AND VICE CHAIR DEPARTMENT OF PATHOLOGY MEDICAL
More informationAgreed by IDWP and VWP September Adopted by CHMP 13 October Start of public consultation 26 October 2016
1 2 3 13 October 2016 EMA/CHMP/360458/2016 Committee for Human Medicinal Products (CHMP) 4 5 6 7 8 Concept paper on preparation of a guideline on the evaluation of medicinal products indicated for the
More informationThorny topics related to CRE control
Thorny topics related to CRE control Michael Lin, MD MPH Rush University Medical Center Chicago CDC Prevention Epicenter 19 th Annual Chicago Infection Control Conference May 30, 2014 Disclosures I have
More informationNovel Approaches to Further Antibacterial Drug Development: New Approaches to the Clinical Development Program
Novel Approaches to Further Antibacterial Drug Development: New Approaches to the Clinical Development Program An industry view John H. Rex, Infection Clinical Vice President AstraZeneca Pharmaceuticals
More informationDisruptive Technology to Guide Precision Antibiotic Therapy
Disruptive Technology to Guide Precision Antibiotic Therapy Company Presentation, October 2018 Forward Looking Statement This presentation includes statements relating to the company's Acuitas AMR Gene
More informationBlood cultures. Sept 2013 A/Prof John Ferguson (nepal)
Blood cultures Sept 2013 A/Prof John Ferguson jferguson@hnehealth.nsw.gov.au www.hicsiganz.org (nepal) Clinical importance Diagnostic : Establishes or confirms the infectious aetiology Provides susceptibility
More information2015 EDITION. Selection. Publications. FAN Plus Media
2015 EDITION of Selection Publications FAN Plus Media INTRODUCTION biomérieux solutions for diagnosing bloodstream infections and sepsis. Sepsis, a systemic inflammation due to infection, can lead to severe
More informationSynagis (Palivizumab) Drug Prior Authorization Protocol
Line of Business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 Synagis (Palivizumab) Drug Prior Authorization Protocol This policy has been developed through review of medical
More informationEnvironmental Surveillance FIDSSA Dr Ben Prinsloo Medical Microbiologist
Environmental Surveillance FIDSSA 2015 Dr Ben Prinsloo Medical Microbiologist The Scientist A scientist, in a broad sense, is a person engaging in a systematic activity to acquire knowledge We require
More informationBlood cultures: past, present and future. Dr Natalia Solomon MD, FRCPSC Medical Microbiologist DynaLIFE Dx
Blood cultures: past, present and future Dr Natalia Solomon MD, FRCPSC Medical Microbiologist DynaLIFE Dx Faculty/ Presenter Disclosure Faculty: Dr Natalia Solomon Relationships with commercial interests:
More informationRSV Prevention in Québec Season
RSV Prevention in Québec 2017 2018 Season Marc H. Lebel, MD, FRCPC Infectious-Diseases Service Dr. Marc Lebel Pediatrician infectiologist at the Sainte Justine Hospital since 1989 Founded the infectious
More informationNDA Requirements: Surveillance, Clinical Trial Data, Breakpoints
NDA Requirements: Surveillance, Clinical Trial Data, Breakpoints Kevin M. Krause Director Microbiology Achaogen, Inc. Presented at the ASM/ESCMID Conference on Drug Development to Meet the Challenge of
More informationEU Regulatory Perspective on RSV vaccines
EU Regulatory Perspective on RSV vaccines EU Perspective No RSV-specific guideline in the EU There is no established EU (i.e. CHMP) position CHMP scientific advice has been given, which reflects current
More informationWP8 Branka Bedenic, University Hospital Zagreb, Croatia Valentino D Onofrio, Jessa hospital and Hasselt University, Belgium
WP8 Branka Bedenic, University Hospital Zagreb, Croatia Valentino D Onofrio, Jessa hospital and Hasselt University, Belgium Inge Gyssens, Jessa hospital and Hasselt University and Radboud University Medical
More informationNEW DRUG FORMULATIONS TO BOOST FIGHT AGAINST RESPIRATORY ILLNESSES AND ANTIBIOTIC-RESISTANT SUPERBUGS
MEDIA RELEASE FOR IMMEDIATE RELEASE 15 September 2014 NEW DRUG FORMULATIONS TO BOOST FIGHT AGAINST RESPIRATORY ILLNESSES AND ANTIBIOTIC-RESISTANT SUPERBUGS A team from A*STAR s Institute of Chemical and
More information55 Industrial Park Road Boothbay, ME USA
Introduction Increasing the level of sanitation and sterility of health-care environments is critical in reducing the transmission of health-care associated infections. The Center for Disease Control estimates
More informationDrug Use Evaluation: Synagis (palivizumab) Summary of Findings:
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Drug Use Evaluation: Synagis (palivizumab) Summary
More informationSetting Clinical Breakpoints/ECOFFS
23 rd August 2016 Setting Clinical Breakpoints/ECOFFS Robin A Howe Antimicrobial use in Primary Care An E. coli is grown from blood cultures Cefuroxime MIC 2mg/L Zone around CXM 30ug disc 27mm Is it sensitive?
More informationBending the Outcome Curve in the Fight Against Sepsis with Real-Time & Predictive Clinical Intelligence
Bending the Outcome Curve in the Fight Against Sepsis with Real-Time & Predictive Clinical Intelligence Adam Klass, Chief Technology Officer, VigiLanz Corporation Bart Abban, Ph.D, Chief Data Scientist,
More informationATTACHMENTS. Attachment 1 "Your Rights under the FMLA of 1993" Notice to be posted of employee rights under FMLA.
File: GCBE-R ATTACHMENTS Attachment 1 "Your Rights under the FMLA of 1993" Notice to be posted of employee rights under FMLA. Attachment 2 "Certification of Health Care Provider" If requested, employee
More informationAntimicrobial Polymers in Medical Devices As Part of the Fight Against Healthcare-Acquired Infections (HAIs)
White Paper Parker Hannifin Corporation Engineered Materials Group 6035 Parkland Blvd. Cleveland, OH 44124 USA +1-714-632-7710 www.parker.com/antimicrobials Antimicrobial Polymers in Medical Devices As
More informationRegulatory hurdles and opportunities
Regulatory hurdles and opportunities Professor Roger Finch Nottingham University Hospitals & University of Nottingham, UK Drug licensing and regulation Mandatory for market authorisation Supports the public
More informationIDSA is pleased to offer the following comments on specific priority areas identified by FDA:
October 31, 2018 Shashi Malhotra Office of Acquisitions & Grants Services (OAGS) Food and Drug Administration Telephone: 240-402-7592 Email: Shashi.Malhotra@fda.hhs.gov SUBJECT: NOT-FD-18-16: Development
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Synagis) Reference Number: CP.PHAR.16 Effective Date: 08.01.09 Last Review Date: 05.18 Line of Business: Commercial, Medicaid, HIM-Medical Benefit Revision Log See Important Reminder
More informationSynagis. Synagis (palivizumab) Description. Section: Prescription Drugs Effective Date: July 1, 2016
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.20.04 Section: Prescription Drugs Effective Date: July 1, 2016 Subject: Synagis Page: 1 of 5 Last Review
More informationInternational Journal of Pure and Applied Mathematics Volume 57 No ,
International Journal of Pure and Applied Mathematics Volume 57 No. 4 2009, 593-603 STATISTICAL PROCESS CONTROL ANALYSIS FOR MONITORING OF DANGEROUS HOSPITAL ACQUIRED INFECTIONS S.K. Uma Maheswaran Department
More informationKey Reasons to Use SAA. Situations Where SAA Has Been Used
Key Reasons to Use SAA More sensitive, more specific and more accurate in diagnosing acute inflammatory conditions than either white blood cells or fibrinogen (see Appendix 1). Real time information in
More informationQuarters 3-4, 2016 & Annual Data provisional 8 th March 2017
Version 1.0 Page 1 of 6 Invasive Pneumococcal Disease in Ireland Bi-annual report by the Health Protection Surveillance Centre Irish Pneumococcal Reference Laboratory, Temple Street Children s University
More informationHealthcare construction
Healthcare construction Role of the Infection Preventionist FIRAS R. ZABANEH, MT( ASCP), CIC, CIE OCT 1, 2015 ( N O T H I N G T O D I S C L O S E ) Current state Many Infection Preventionists view their
More informationRapid Diagnostic Tests in Microbiology (PAs & PHs) I.Afeke UHAS
Rapid Diagnostic Tests in Microbiology (PAs & PHs) I.Afeke UHAS Positive Negative Objective: Upon completion of this topic, the student should be able to: What a rapid diagnostic test (RDT) is When a RDT
More informationPublic Health Adaptation to Climate Change: Air Quality Challenges
Public Health Adaptation to Climate Change: Air Quality Challenges George Luber, PhD Climate and Health Program Division of Environmental Hazards and Health Effects National Center for Environmental Health
More informationFAMILY AND MEDICAL LEAVE ACT OF 1993
Division of Administrative Services HUMAN RESOURCES FAMILY AND MEDICAL LEAVE ACT OF 1993 Employee Packet Division of Administrative Services HUMAN RESOURCES North End Center 300 Turner St. NW Suite 2300
More informationMICROBIOLOGY SPECIMEN TRANSPORT GUIDELINES
SPECIMEN TRANSPORT GUIDELINES Specimen Transport System/Container Maximum Time (Hours) Viable Refrigerated 4 C. Room Temperature 25 C. Anaerobes Only Blood Culture Gel(Starplex) Starswab or Port-A-Cult
More informationClinical Policy: Palivizumab (Synagis) Reference Number: ERX.SPA.124 Effective Date: Last Review Date: 08.17
Clinical Policy: (Synagis) Reference Number: ERX.SPA.124 Effective Date: 10.01.16 Last Review Date: 08.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationSyndromic Testing System
Syndromic Testing System System Overview What is syndromic testing? Most often, patients with infectious illnesses have signs and symptoms that are indicative of a disease, but are not specific enough
More informationHow to Prevent Central Line- Associated Sepsis in the NICU
How to Prevent Central Line- Associated Sepsis in the NICU Professor of Pediatrics, Molecular Virology and Microbiology International Symposium on Neonatology Texas Children s Hospital Sao Paulo, Brazil
More informationCDC s Environmental Public Health Tracking Program
CDC s Environmental Public Health Tracking Program Gary P. Noonan Acting Chief, MPA, RS, DLAAS Environmental Health Tracking Branch Division of Environmental Hazards and Health Effects National Center
More informationCystic Fibrosis and anaerobes. Dr Michael Tunney, Clinical & Practice Research Group, School of Pharmacy, Queen s University Belfast.
Cystic Fibrosis and anaerobes Dr Michael Tunney, Clinical & Practice Research Group, School of Pharmacy, Queen s University Belfast. Outline Background CF: the disease Recent developments in CF Detection
More informationCME/SAM. Clinical Laboratory Detection of AmpC β-lactamase Does It Affect Patient Outcome?
Microbiology and Infectious Disease / Laboratory Detection of AmpC β-lactamase Clinical Laboratory Detection of AmpC β-lactamase Does It Affect Patient Outcome? Kenneth H. Rand, MD, 1 Bradley Turner, MD,
More informationIQCP Inspector Training Scenarios
Scenario 1: You are reviewing the product insert for a non-waived point of care blood gas analyzer that uses a cartridge for each patient sample to provide ph, po2 and pco2 results. The manufacturer s
More informationGenome Sequencing: Applications and Newborn Screening. June 2, 2014
Genome Sequencing: Applications and Newborn Screening June 2, 2014 Suzanne Cordovado, PhD Molecular Quality Improvement Program Centers for Disease Control and Prevention National Center for Environmental
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
Generic Brand HICL HCN Exception/Other PALIVIZUMAB SYNAGIS 18564 Synagis may be covered during the RSV season from October 15, 2017 and March 31, 2018. If the PA is received prior to October 15, 2017,
More informationGenMark Diagnostics. eplex BLOOD CULTURE IDENTIFICATION (BCID): DESIGNED TO IMPROVE PATIENT CARE AND CLINICAL OUTCOMES
GenMark Diagnostics eplex BLOOD CULTURE IDENTIFICATION (BCID): DESIGNED TO IMPROVE PATIENT CARE AND CLINICAL OUTCOMES Association for Molecular Pathology (AMP) November 15, 2017 Agenda eplex: True Sample-to-Answer
More informationPrevention of Transmission of the Superbug Carbapenem-Resistant Enterobacteriaceae (CRE) during Gastrointestinal Endoscopy
Prevention of Transmission of the Superbug Carbapenem-Resistant Enterobacteriaceae (CRE) during Gastrointestinal Endoscopy Sponsored by: Presentation by: Lawrence F. Muscarella, Ph.D. President LFM Healthcare
More informationCatheter-related infections: practical aspects in 2003
Catheter-related infections: practical aspects in 2003 A joint meeting of the Société Belge d'infectiologie et de Microbiologie Clinique / Belgische Vereniging voor Infectiologie en Klinische Microbiologie
More informationChicago Ebola Preparedness Update. Suzet McKinney, DrPH, MPH, Deputy Commissioner Stephanie Black, MD, MSc, Medical Director March 18, 2015
Chicago Ebola Preparedness Update Suzet McKinney, DrPH, MPH, Deputy Commissioner Stephanie Black, MD, MSc, Medical Director March 18, 2015 Agenda Ebola Overview Crisis in West Africa Symptoms and transmission
More informationSilvaClean Antimicrobial Laundry Additive
SilvaClean Antimicrobial Laundry Additive Frequently Asked Questions What role do textiles play in the spread of infection? Healthcare textiles in the patient environment such as bed linen, gowns, and
More informationMicrobiology of Healthcare-associated Infections
Microbiology of Healthcare-associated Infections William A. Rutala, Ph.D., M.P.H. Director, Statewide Program for Infection Control and Epidemiology and Professor of Medicine, University of North Carolina
More informationFMLA Employer Response Form
FMLA Employer Response Form Employer Response to Employee Request for Family or Medical Leave (Optional: use form see 29 CFR 825.301 (Family and Medical Leave Act of 1993) U.S. Department of Labor Employment
More information(For National Authority Use only)
Page 2 Medlmmune, Inc. Name ofactive Ingredient: PROTOCOL SYNOPSIS Title: A Phase II Study ofthe Safety, Tolerance,Phannacokinetics,and Effect on Viral Load in Tracheal Aspirates ofmedi-493, a Humanized
More informationGoals. Create a tool to manage a ubiquitous, complex clinical process. Deploy the tool in the ICUs and ED. Evaluate changes in clinical practice
A Model-Integrated Approach to Implementing Individualized Patient Care Plans Based on Guideline- Driven Clinical Decision Support and Process Management Jason B. Martin, MD, Janos L. Mathe, Peter Miller,
More informationMicrobiology for Oral and Topical Products - The basics Scott Colbourne Business Manager NSW ALS Food & Pharmaceutical
Microbiology for Oral and Topical Products - The basics Scott Colbourne Business Manager NSW ALS Food & Pharmaceutical RIGHT S O L U T I O N S RIGHT PARTNER Contents TGO 77 - Introduction Tests Performed
More informationEnvironmental Health Investigations During Outbreaks
Environmental Health Investigations During Outbreaks Max Zarate-Bermudez, Ph.D. 8 th Annual OutbreakNet Meeting August 30, 2012 National Center for Environmental Health Division of Emergency and Environmental
More informationForecast diagnostics for antimicrobial resistance (AMR)
Forecast diagnostics for antimicrobial resistance (AMR) Authors: Ann Van den Bruel, Philip Turner NIHR Diagnostic Evidence Cooperative Oxford, University of Oxford Context When asked to make forecasts
More informationVersion 1.0v Page 1 of 5 Invasive Pneumococcal Disease in Ireland
Version 1.0v Page 1 of 5 Invasive Pneumococcal Disease in Ireland A Bi-annual report by the Health Protection Surveillance Centre and the Irish Pneumococcal Reference Laboratory at the Department of Clinical
More informationObtaining an effluent sample of peritoneal dialysis fluid Procedure for. Contents
Obtaining an effluent sample of peritoneal Procedure for Classification: Procedure Lead Author; Joanne Martin Authors Division: Renal Services Unique ID TC51(05) Issue number: 4 Expiry Date: April 2019
More informationDisinfection of stainless steel in hospitals
Disinfection of stainless steel in hospitals Summary of a report by Manchester Metropolitan University and AgroParisTech www.teamstainless.org 2 Introduction Thanks to its unique properties, stainless
More informationRE: Season for Respiratory Syncytial Virus Prophylaxis for High-Risk Infants
Ministr y o f He alth and Lon g-term Ca re Ontario Public Drug Programs Division Drug Programs Delivery Branch 3 rd Floor, 5700 Yonge Street Toronto ON M2M 4K5 Telephone: (416) 327-8109 Toll Free: 1-866-811-9893
More informationRobert Martin, MPH, DrPH President, Diagnostic Microbiology Development Program Kathmandu, Nepal, May 2018
Laboratory Strengthening and the Robert Martin, MPH, DrPH President, http://dmdp.org Kathmandu, Nepal, May 2018 Global Burden of Infectious Disease DALY = Disability Adjusted Life Year Infectious diseases
More informationOverview. A day in the life. 8/31/2012. Walkthrough of a typical run. Training, maintenance and QC. Ah ha! moments
David Winkler MT(ASCP) Microbiology Technical Specialist St. Louis Children s Hospital No financial disclosures Overview Walkthrough of a typical run - Benefits to patient care, cost savings, changes in
More informationPlatelet Factor IV- Heparin Antibodies. Presenter: Michael J. Warhol, M.D.
Platelet Factor IV- Heparin Antibodies Presenter: Michael J. Warhol, M.D. Learning Objectives Describe the mechanism of interaction between Heparin and Platelet Factor 4 Review the chemistry of Heparin
More informationRegulatory considerations for initiating paediatric trials with RSV antivirals
Regulatory considerations for initiating paediatric trials with RSV antivirals Irmgard Eichler European Medicines Agency Expert meeting on RSV therapeutics March 2016 An agency of the European Union In
More informationIf your name starts with a C, we are looking for you!!
Active surveillance for C. diff, CRE, (and Candida auris) in Houston If your name starts with a C, we are looking for you!! Kevin W. Garey, PharmD, MS, FASHP Professor and Chair Dept of Pharmacy Practice
More information10/13/2017. The Christiana Care Way Awards PDCA Template Title goes here 1. Opportunity for Improvement. Team Members
A Comparative Pilot Study of Supply Tray Management in the Medical Intensive Care Unit: Repeated use Versus Exchanged Supply Tray and Tray Contents Jill Kane MSN, RN, CCRN Lynn Bayne PhD, APRN, NNP-BC
More informationSCOTTISH Salmonella, Shigella & C.difficile REFERENCE LABORATORY (SSSCDRL)
SCOTTISH Salmonella, Shigella & C.difficile REFERENCE LABORATORY (SSSCDRL) Title User Manual LABORATORY PROCEDURE NUMBER / VERSION DATE OF ISSUE 15/09/2016 REVIEW INTERVAL AUTHORISED BY AUTHOR 2 Years
More informationJoy Allen, William Jones, Michael Power, Stephen Rice, Greg Mantiapolous, Mark Wilcox, and Ashley Price
What is the potential for point of care diagnostics to improve testing protocols for C. difficile infection, with particular reference to the English NHS? Joy Allen, William Jones, Michael Power, Stephen
More informationNew York University UNIVERSITY POLICIES
New York University UNIVERSITY POLICIES Title: D.C. FMLA Policy and Procedure Effective Date: April 30, 2018 Supersedes: September 1, 2016 Issuing Authority: Executive Vice President Responsible Officer:
More informationNHSN Analytics For real (and busy!) people
NHSN Analytics For real (and busy!) people Part 2 Accessing and Displaying Data Jamie Moran, MSN, RN, CMSRN, CIC Martha Jaworski, MS,RN, CIC June 12, 2015 Qualis Health A leading national population health
More informationRequest for Prior Authorization for Synagis (palivizumab) Website Form Submit request via: Fax
Request for Prior Authorization for Synagis (palivizumab) Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 All requests for Synagis (palivizumab) require a Prior Authorization
More informationAntisera QC and IQCP and Associated Challenges
Antisera QC and IQCP and Associated Challenges Patti Fields Enteric Diseases Laboratory Branch (EDLB) CDC 2017 APHL Annual Meeting Providence, Rhode Island June 14, 2017 National Center for Emerging and
More informationFAMILY AND MEDICAL LEAVE ACT OF 1993
Division of Administrative Services HUMAN RESOURCES FAMILY AND MEDICAL LEAVE ACT OF 1993 Family Packet Division of Administrative Services HUMAN RESOURCES North End Center 300 Turner St. NW Suite 2300
More informationNETSCC, HTA 26th July 2009
NETSCC, HTA 26 th July 2009 HTA 06/29/02 1 Title of the project: Palivizumab for immunoprophylaxis of respiratory syncitial virus (RSV) bronchiolitis in high risk infants, additional subgroup analysis
More informationAdvances in Medical Microbiology - Are the Patients Better Off?
Advances in Medical Microbiology - Are the Patients Better Off? R.P. Rennie Professor Emeritus. Laboratory Medicine and Pathology University of Alberta. Clinical Microbiology Consultant Alberta Health
More informationInfectious Complications in Vascular Patients
Infectious Complications in Vascular Patients Shireesha Dhanireddy, MD Medical Director, Infectious Disease Clinic Harborview Medical Center Associate Professor, Department of Medicine University of Washington
More informationTwo-Dimensional (2D) Vaccine Barcode Pilot Project
Two-Dimensional (2D) Vaccine Barcode Pilot Project Association of Immunization Managers / Immunization Program Managers Meeting February 3, 2012 Ken Gerlach, MPH, CTR Immunization Services Division National
More informationVerification of Gradient Diffusion Strips
Verification of Gradient Diffusion Strips Objectives 1. Describe gradient diffusion tests 2. Describe process of FDA clearance of susceptibility tests 3. Discuss CLIA requirements for laboratory verification
More informationEbola Virus Disease Q&As for Nova Scotia Health Care Workers
EBOLA VIRUS DISEASE Ebola virus disease is a severe disease that causes hemorrhagic fever in humans and animals. While the likelihood of a case presenting in Nova Scotia is very low, the province s health
More informationNovel Technologies in Microbiology
Novel Technologies in Microbiology BENEFITS BEYOND THE LAB Susan M. Poutanen, MD, MPH, FRCPC Microbiologist/ID Consultant, UHN/MSH Associate Professor, U. of Toronto AMMI Canada CACMID May 4, 2017 Disclosures
More informationExecutive War College, Project Santa Fe May 4, 2018 New Orleans, LA
Executive War College, Project Santa Fe May 4, 2018 New Orleans, LA Presented by Geisinger Diagnostic Medicine Institute (DMI) Donna M. Wolk, MHA, Ph.D., D(ABMM) Objectives Review background/relevant core
More informationSCOTTISH Salmonella, Shigella & C.difficile REFERENCE LABORATORY (SSSCDRL)
SCOTTISH Salmonella, Shigella & C.difficile REFERENCE LABORATORY (SSSCDRL) Title User Manual LABORATORY PROCEDURE NUMBER / VERSION SSSCDRL_UM_2017 DATE OF ISSUE 20/10/2017 REVIEW INTERVAL AUTHORISED BY
More informationCRE is not the first organism we ve had that has become resistant to antibiotics, so why is it so important? CRE resistance is complex because it can
1 Enterobacteriaceae are a large family of bacteria that are a normal part of a person's digestive system (2). Examples include Escherichia coli and species of the genera Klebsiella, Enterobacter, Serratia,
More informationEVIDENCE-BASED PAPER - CONTINUOUS AND INTERMITTENT IV SETS
EVIDENCE-BASED PAPER - CONTINUOUS AND INTERMITTENT IV SETS THE CLINICAL QUESTION What is the difference between I.V. administration sets used for continuous infusion and those used for intermittent infusion?
More informationVerification of Disk Diffusion Tests
Verification of Disk Diffusion Tests Objectives 1. Describe disk diffusion tests 2. Describe process of FDA clearance of susceptibility tests 3. Discuss CLIA requirements for laboratory verification of
More informationJohan W Mouton Canisius-Wilhelmina Hospital Nijmegen, The Netherlands
Can pk/pd replace clinical trials? Johan W Mouton Canisius-Wilhelmina Hospital Nijmegen, The Netherlands The Traditional Approach Phase Participants Research questions Number Characteristics I 10-50 Usually
More informationLegionella. Anna Frick, MPH, CIC Kim Spink RN, BSN, CIC
Legionella Anna Frick, MPH, CIC Kim Spink RN, BSN, CIC Legionella Gram negative, flagellated bacteria Many species; several serogroups L. pneumophila Serogroup 1 is the most common All species and serogroups
More informationProof-of-principle antimicrobial resistance routine diagnostics surveillance project (PoP project)
PROTOCOL Proof-of-principle antimicrobial resistance routine diagnostics surveillance project (PoP project) Version 2.0 PROTOCOL Proof-of-principle antimicrobial resistance routine diagnostics surveillance
More informationARTICLE July SAJCC 2010, V ol. 26, No.
ARTICLE Soluble triggering receptor expressed on myeloid cells (s-trem-1) from endotracheal aspirates in critically ill patients: A potential marker of the dynamic inflammatory burden of the lower respiratory
More informationWake Forest Baptist Medical Center Guideline for Use of Ribavirin in the Treatment of Respiratory Syncytial Virus (RSV) Infection
Wake Forest Baptist Medical Center Guideline for Use of Ribavirin in the Treatment of Respiratory Syncytial Virus (RSV) Infection General Information Aerosolized ribavirin has been shown in limited clinical
More informationWake Forest Baptist Medical Center Guideline for Use of Ribavirin in the Treatment of Respiratory Syncytial Virus (RSV) Infection
Wake Forest Baptist Medical Center Guideline for Use of Ribavirin in the Treatment of Respiratory Syncytial Virus (RSV) Infection General Information Aerosolized ribavirin has been shown in limited clinical
More informationBiofilm Protocol Optimization For Pseudomonas aeruginosa. Introduction. Materials and Methods. Culture Media, Incubation Time, and Biofilm Measurement
Biofilm Protocol Optimization For Pseudomonas aeruginosa Culture Media, Incubation Time, and Biofilm Measurement Introduction In addition to the conventional arsenal of antibiotic resistance mechanisms
More informationDrug Utilization Review: Palivizumab (Synagis ; Medimmune)
Background Respiratory syncitial virus (RSV) is a highly contagious virus that is estimated to infect nearly all children by 3 years of age, and is the leading cause of serious lower respiratory tract
More informationEndoscope Microbial Surveillance Testing Made Easy
Endoscope Microbial Surveillance Testing Made Easy Alpa Patel, B.S.RM (NRCM) Senior Scientist Nelson Laboratories Kaumudi Kulkarni, M.S. Manager of Research and Development Healthmark Industries Disclosure
More information